Douglas J Hughes's most recent trade in Immunovant Inc was a trade of 16,188 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 16,188 | 135,773 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,600 | 7,600 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | J. Douglas Hughes | Director | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 02 Dec 2024 | 5,425 | 119,585 (0%) | 0% | 28.5 | 154,830 | Common Stock |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 11,255 | 125,010 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 4,690 | 4,690 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 16,260 | 16,260 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 12,523 | 113,755 (0%) | 0% | 0 | Common Stock | |
| Eargo Inc | Douglas J. Hughes | Director | 22 Nov 2022 | 71,363 | 107,072 | - | 0.5 | 35,682 | Common Stock | |
| Eargo Inc | Douglas J. Hughes | Director | 22 Nov 2022 | 7,500 | 0 | - | - | Subscription Rights (right to buy) | ||
| Eargo Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 74,074 | 74,074 | - | - | Stock Options (Right to Buy) | |
| Eargo Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 74,805 | 74,805 | - | - | Stock Options (Right to Buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 31,668 | 31,668 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 21,059 | 101,232 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 71,492 | 208,973 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 21,726 | 80,173 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Douglas J. Hughes | Director | Purchase of securities on an exchange or from another person at price $ 8.24 per share. | 27 Aug 2021 | 18,247 | 58,447 (0%) | 0% | 8.2 | 150,355 | Common Stock |
| Eargo Inc | Douglas J. Hughes | Director | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 27 Apr 2021 | 1,500 | 35,709 | - | 55 | 82,500 | Common Stock |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 23,300 | 23,300 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Douglas J. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 15,500 | 40,200 (0%) | 0% | 0 | Common Stock | |
| Eargo Inc | Douglas J. Hughes | Director | 20 Oct 2020 | 37,209 | 37,209 | - | - | Common Stock | ||
| Eargo Inc | Douglas J. Hughes | Director | 20 Oct 2020 | 33,259 | 0 | - | - | Series C Preferred Stock |